Special Issue

Morpho-Molecular and Genetic Basis of Cardiomyopathies

Message from the Guest Editor

Cardiomyopathies describe heart muscle diseases with different structural and hemodynamic profiles (Hypertrophic, dilated and restrictive), and uncertainty around their causes and mechanisms of damage still remains. Inflammatory cardiomyopathy is a large area of clinical interest where the clear identification of infectious agents (sometimes in combination) and the immune pathogenic mechanisms is difficult, with the limited sharable indications of myocardial inflammation hindering treatment. Recognition of the morpho-molecular and genetic basis of cardiomyopathies is crucial for accurately defining treatment as well as improving patient prognosis. In fact, many cardiomyopathies with a genetic basis (i.e., lysosomal storage diseases) have become treatable; however, resistance to enzyme replacement therapy is an increasing problem as the drug's pharmacokinetics remain unclear. One aim of the present Special Issue is to explore the mechanisms of these flaws and improve the drug's therapeutic impact.

Guest Editor

Dr. Andrea Frustaci

Cellular and Molecular Cardiology Lab, National Institute for Infectious Diseases L. Spallanzani, Rome, Italy

Deadline for manuscript submissions

30 June 2026

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/244649

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).